Apigenin shows up in bone-cell research because it interacts directly with the two cell types that build and break down bone: osteoblasts (which form new bone) and osteoclasts (which resorb it). The research is real, mechanistically detailed, and entirely preclinical: conducted in cultured bone cells and in mice with surgically induced bone loss, not in people. It’s also, notably, not fully consistent across studies. Here’s what was actually measured, and where the findings disagree.
Key Takeaways
- In cultured mouse osteoclast precursor cells, apigenin suppressed the cytokines and cell-surface markers needed for osteoclasts to form and resorb bone.
- In mice with surgically removed ovaries (a standard model for postmenopausal bone loss), an injected apigenin dose reduced trabecular bone loss measured by CT scan.
- The same 2015 study found apigenin also suppressed osteoblast differentiation markers in a dish, which is the opposite of what you’d want for a pro-bone-formation supplement claim.
- Other, more recent studies are reported to show apigenin promoting osteoblast differentiation instead of inhibiting it, but none is cited on this page [2]the field has not resolved this contradiction.
- No human trial has measured apigenin’s effect on bone density, fracture risk, or any clinical bone outcome.
The Osteoclast Findings: Reasonably Consistent
The clearest finding in the apigenin bone studies cited here concerns osteoclasts [1][2], the cells responsible for breaking down bone tissue. A 2006 study using mouse calvarial osteoblast cells (MC3T3-E1) and the RAW 264.7 osteoclast precursor cell line found that apigenin inhibited TNF-alpha- and interferon-gamma-induced secretion of osteoclastogenic cytokines from osteoblasts, and separately suppressed RANKL-induced expression of TRAP, RANK, and calcitonin receptor in osteoclast precursors: the specific markers needed for precursor cells to fuse into mature, bone-resorbing osteoclasts. The practical effect was fewer multinucleated osteoclasts forming under conditions that would normally drive their formation.[1] This anti-resorptive mechanism is the basis for most of the “apigenin may help prevent bone loss” framing that shows up in supplement marketing.
The Ovariectomized-Mouse Model: What the In Vivo Data Actually Showed
A 2015 study went further, testing apigenin in ovariectomized mice: a model that mimics postmenopausal estrogen loss and the resulting accelerated bone turnover. Mice given injected apigenin at 10 mg/kg body weight showed significantly less trabecular bone loss in the femur, measured by X-ray CT, compared to untreated ovariectomized controls. That’s a genuine in vivo protective signal. But the same study also tested apigenin directly on cultured osteoblasts (MC3T3-E1 cells) and found it markedly inhibited cell proliferation, collagen production, alkaline phosphatase activity, and calcium deposition, all standard markers of osteoblast differentiation and new bone formation, at concentrations of just 1 to 10 micromolar.[2] In other words, in this study apigenin protected against bone loss by suppressing osteoclast-driven resorption, not by boosting new bone formation, and it actually suppressed the osteoblast side of the equation in a dish.
Research note: In high-fat-diet and ob/ob mice, apigenin acted on PPARgamma and shifted macrophages toward the M2 type; unlike rosiglitazone it did not cause significant weight gain or osteoporosis. Mouse and cell data [3].
The Contradiction: Later Studies Report the Opposite Osteoblast Effect
This is where the research gets genuinely unsettled. Some later studies on mesenchymal stem cells and osteoblast precursors are reported to find the opposite, that apigenin promotes osteogenic differentiation and mineralization, but none of them is cited on this page, so it cannot weigh them against the cell work above [2]. Whether the osteoblast effect depends on cell type, concentration, or experimental model is not established by the studies cited here [2]. This isn’t a case where “more research is needed” is a throwaway line: it’s a real, acknowledged, and currently unresolved conflict between published findings on the same compound’s core mechanism in bone cells.
What This Means for a Bone Health Claim
Taken together, the evidence supports a specific, narrow claim: apigenin has a demonstrated anti-osteoclastogenic (anti-resorptive) effect in cultured cells and reduced bone loss in one ovariectomized-mouse model. It does not currently support a broader “apigenin builds bone” or “apigenin increases bone density” claim, both because the osteoblast-side evidence is contradictory across studies and because none of this has been tested in a human trial with dietary or supplemental apigenin doses, as opposed to the injected doses used in the mouse model. People concerned about bone density from osteoporosis, menopause, or age-related bone loss should treat apigenin as an active but unresolved area of preclinical research, not a substitute for established interventions like calcium, vitamin D, resistance training, or prescribed bone-density medication.
Bottom Line
Apigenin suppressed osteoclast formation and activity in cultured cells [1], and reduced bone loss in one ovariectomized-mouse model. Its effect on osteoblasts, the cells that build new bone, is unsettled: the cell work cited here showed inhibition, and promotion is reported elsewhere but not cited on this page [2]. No human study has tested apigenin for bone density or fracture outcomes. The osteoclast-suppression mechanism is real and interesting; a bone-health supplement claim built on it is not yet supported by the full body of evidence.
Frequently Asked Questions
Does apigenin help with bone density or osteoporosis?
In cell studies, apigenin suppresses osteoclast formation and activity, and reduced bone loss in one ovariectomized-mouse model of postmenopausal bone loss. No human trial has tested apigenin for bone density or osteoporosis outcomes.
Does apigenin build new bone or just prevent bone loss?
The research is unsettled. The cell work cited here found apigenin inhibits osteoblast activity (the cells that build new bone), and other studies are reported to find it promotes osteoblast differentiation but are not cited here. The anti-osteoclast (anti-resorptive) effect was seen in the cited cell work, and one mouse study found less bone loss with injected apigenin [1][2].
Should I take apigenin for osteoporosis instead of standard treatment?
No. Apigenin bone research is entirely preclinical (cell and mouse studies), with no human trials on bone density or fracture outcomes. It should not replace calcium, vitamin D, resistance training, or medications prescribed for osteoporosis.
References
- Bandyopadhyay S, Lion JM, Mentaverri R, et al. Attenuation of osteoclastogenesis and osteoclast function by apigenin. Biochemical Pharmacology (2006). PMID 16750176
- Goto T, Hagiwara K, Shirai N, et al. Apigenin inhibits osteoblastogenesis and osteoclastogenesis and prevents bone loss in ovariectomized mice. Cytotechnology (2015). PMID 24500394
- Feng X et al. Activation of PPARγ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage Polarization. EBioMedicine (2016). PMID 27374313
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
